MedTrace Logo

A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects

NCT03279146 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2018-08-02

No results posted yet for this study

Summary

This is a Phase 1 study to evaluate the PK profile of TXL oral formulations in healthy subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

Tenofovir exalidex (TXL)

Oral formulations

Sponsors & Collaborators

  • ContraVir Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • John Sullivan-Bolyai, MD, MPH · ContraVir Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-06
Primary Completion
2018-06-09
Completion
2018-06-16
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03279146 on ClinicalTrials.gov